Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Inventory (2016 - 2025)

Adma Biologics' Change in Inventory history spans 13 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 725.67% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $36.2 million, up 1456.42%, while the annual FY2025 figure was $36.2 million, 1456.42% up from the prior year.
  • Change in Inventory reached $9.8 million in Q4 2025 per ADMA's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $19.3 million in Q2 2025 to a low of -$8.0 million in Q3 2024.
  • Average Change in Inventory over 5 years is $6.2 million, with a median of $5.4 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: skyrocketed 2571.53% in 2023, then plummeted 699.48% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $10.6 million in 2021, then tumbled by 96.54% to $366457.0 in 2022, then surged by 2571.53% to $9.8 million in 2023, then crashed by 116.0% to -$1.6 million in 2024, then skyrocketed by 725.67% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Change in Inventory are $9.8 million (Q4 2025), $5.2 million (Q3 2025), and $19.3 million (Q2 2025).